Elevation Pharmaceuticals

Elevation Pharmaceuticals, Inc. was a San Diego-based biopharmaceutical company established in 2008 by a team of experienced entrepreneurs including Bill Gerhart, who served as President and CEO, Cam Garner, and Ahmet Tutuncu. Gerhart, a seasoned biotech executive with an MBA from Harvard Business School, brought a track record of successfully launching and financing life science companies. His strategy centered on repurposing previously approved drugs for new therapeutic applications, a model he viewed as a more efficient and lower-risk approach to pharmaceutical development.

The company's core business was the development of novel aerosol therapies for patients with respiratory diseases. Elevation specifically targeted the unmet needs of individuals with moderate to severe chronic obstructive pulmonary disease (COPD) who were unable to effectively manage their condition with standard dry powder or metered-dose inhalers. The business model focused on advancing its lead product candidate through clinical trials to demonstrate its value and attract acquisition by a larger pharmaceutical entity.

Elevation's principal asset was EP-101, a proprietary inhalation solution of glycopyrrolate, a long-acting muscarinic antagonist (LAMA). This therapy was designed for delivery via a customized, portable eFlow® Nebulizer System, licensed from PARI Pharma, which optimized drug delivery with treatment times of less than three minutes. The key benefit of this drug-device combination was to reduce the significant treatment burden for patients who often required multiple daily doses with longer administration times using traditional nebulizers. After successful Phase 2b clinical trials demonstrated significant improvements in lung function, the company achieved a major milestone. This success culminated in August 2012, when Sunovion Pharmaceuticals Inc. announced its definitive agreement to acquire Elevation for an upfront payment of $100 million, with potential for up to $330 million in additional milestone payments, for a total deal value of $430 million. The acquisition was completed in September 2012, and Elevation became a wholly-owned subsidiary of Sunovion.

Keywords: Elevation Pharmaceuticals, Bill Gerhart, COPD treatment, aerosol therapy, EP-101, glycopyrrolate, nebulizer, LAMA, respiratory disease, biopharmaceutical, Sunovion acquisition, eFlow Nebulizer, drug repurposing, clinical trials, Cam Garner, inhaled therapies, chronic obstructive pulmonary disease, pharmaceutical development, life sciences, venture capital